ClinicalTrials.gg
RecruitingNCT06299787CDiA-P4Updated Mar 8, 2024

Cognitive Dysfunction in the Addictions Study - Project 4 (P4)

An interventional study of intermittent theta burst stimulation and Sham stimulation in Major Depressive Disorder and Alcohol Use Disorder, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Feb 2022, registered Oct 2022).
  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health — 10 open to participants now, 13 under way, none of them phase 3. Depressive Disorder, Major · Centre for Addiction and Mental Health.

Planned enrollment
32nd of 44
40 · median 72
Started
2022
with 3 others
No phase
36 of 48
6 open now
Primary completion
2024-12
later than 2 of 12 live
Registered
41st of 48
by date

Among the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, this one is the 32nd largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2022, is one of 36 with no phase, reaches primary completion later than 2 of the 12 other live ones, and was the 41st registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

10 of the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, or all of them as a file.
02

Study summary

The prefrontal cortex, although well established as an efficacious target for the treatment of major depressive disorder (MDD), has recently come into favour as a therapeutic target for alcohol use disorders (AUD). Depressive symptoms are also highly prevalent in individuals with AUD. A number of cognitive and psychological processes stemming from the prefrontal cortex, a common treatment target for repetitive transcranial magnetic stimulation (rTMS), are disrupted in both MDD and AUD. The proposed study will enhance the development of theta burst stimulation (TBS) as a new intervention for AUD in the context of depressive symptoms and uses integrated TMS-EEG to identify neurophysiological targets of executive dysfunction in this disorder.

Read the detailed description

The prefrontal cortex, although well established as an efficacious target for the treatment of major depressive disorder (MDD), has recently come into favour as a therapeutic target for alcohol use disorders (AUD). Depressive symptoms are also highly prevalent in individuals with AUD. A number of cognitive and psychological processes stemming from the prefrontal cortex, a common treatment target for repetitive transcranial magnetic stimulation (rTMS), are disrupted in both MDD and AUD. The proposed study will enhance the development of theta burst stimulation (TBS) as a new intervention for AUD in the context of depressive symptoms and uses integrated TMS-EEG to identify neurophysiological targets of executive dysfunction in this disorder.

03

Conditions studied

  • Major Depressive Disorder
  • Alcohol Use Disorder
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. are outpatients;
  2. are voluntary and competent to consent to treatment;
  3. have a Diagnostic and Statistical Manual for Mental Disorders, 5th edition () diagnosis of AUD based on the MINI;
  4. do not exhibit problematic use of any substances (excluding nicotine and caffeine), including alcohol, for >1 month;
  5. are male or female between the ages of 18 - 59;
  6. screened positive for an MDE based on the MINI without psychotic symptoms
  7. are agreeable to keeping their current antidepressant medications and medications for alcohol use disorder constant during the study;
  8. are reliably taking SUD agonist therapies if appropriate and managed by their clinical team;
  9. are able to adhere to the study schedule;
  10. meet the TMS safety criteria.

Exclusion criteria

Exclusion Criteria:

  1. have a concomitant major unstable medical illness;
  2. are pregnant or intend to get pregnant during the study;
  3. have possible or probable dementia (based on the Informant Questionnaire on Cognitive Decline in the Elderly that will be administered to any participant with a baseline total score of \< 26 on the (MoCA);
  4. have failed a course of ECT, due to the lower likelihood of response to rTMS;
  5. have any significant neurological disorder (e.g., a space occupying brain lesion, a history of stroke, a cerebral aneurysm, a seizure disorder, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant history of head trauma with radiological evidence of intracranial trauma at the time of injury due to risk of possible seizure foci from prior intracranial lesions.
  6. present with a medical condition, a medication, or a laboratory abnormality that could cause a major depressive episode or significant cognitive impairment in the opinion of the investigator (e.g., hypothyroidism with low TSH, Cushing's disease);
  7. have an intracranial implant (e.g., aneurysm clips, shunts, cochlear implants) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
  8. require a benzodiazepine with a dose equivalent to lorazepam 2 mg/day or higher or any anticonvulsant due to the potential of these medications to limit the efficacy of rTMS [79];
  9. have an inability to communicate in English fluently enough to complete the clinical assessments.
  10. have a MINI diagnosis or active symptoms of Bipolar Disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Active Bilateral

    Bilteral TBS, applied as cTBS over the right DLPFC followed by iTBS over the left DLPFC

    Device: intermittent theta burst stimulation

  • Sham comparator
    Sham

    Sham TBS

    Device: Sham stimulation

Interventions

  • Deviceintermittent theta burst stimulation

    Theta-burst stimulation

  • DeviceSham stimulation

    Stimulation with double-sided B70-type coil

06

What researchers measure

Primary outcomes

  1. Executive Function Index - inhibition

    Flanker task

    Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)

  2. Executive Function Index - working memory

    N-back task

    Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)

  3. Executive Function Index - set shifting

    switch task

    Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)

Secondary outcomes

  1. 17-Item Hamilton Depression Rating Scale (HRSD-17)

    Decrease in 17-Item Hamilton Depression Rating Scale score, 0 is lowest value, 52 is highest, higher value = more severe depression

    Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)

Other outcomes

  1. Columbia-Suicide Severity Rating Scale

    Decrease in Columbia-Suicide Severity Rating Scale score, 0 is lowest score, 25 is highest, higher value = more suicidal ideation

    Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Dec 2024, 34 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 34 months is close to that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2022
First posted
Mar 8, 2024
StartActual
Feb 7, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jul 1, 2025
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06299787
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Feb 7, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Jul 1, 2025 (estimated)
Last update
Mar 8, 2024

Study contacts

Daphne Voineskos, MD
Contact
daphne.voineskos@camh.ca
416-535-8501 ext. 30176

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion